Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05200702
Other study ID # Exo-NMD1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 5, 2022
Est. completion date July 2024

Study information

Verified date September 2023
Source Institut de Myologie, France
Contact Guillaume Bassez, MD
Phone 01 42 16 66 43
Email guillaume.bassez@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aims of the current study are as follow: i) Evaluate the safety, usability, and acute efficiency of a powered knee-hip dermoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland) in patients with neuromuscular disorders, ii) Elaborate recommendations regarding usability criteria for safe and efficient use the device in patients with neuromuscular disorders (e.g. type and severity of patient's functional deficits), iii) generate necessary data to foresee a future study involving a home use of the device and assessment of long-term benefits.


Description:

Patients with neuromuscular disorders display different type of symptoms depending on the type of pathology. Diseases like facioscapulohumeral dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD2b), sporadic inclusion body myositis (SIBM) or Pompe disease (PD) are characterized by severe muscle weakness leading to reduced functional capacities. This leads to a dramatic decrease of quality of life (e.g. reduced autonomy/participation, social isolation, depression) associated with increased fall risk and complications (e.g. trauma, cardio-vascular issues, trauma, chronic pain, loss of bone mass, and weight gain). However, a residual of level of strength and residual function may be maintained over years, even at severe disease stages allowing transfers and ambulation. However, the maintenance of this type of activity is often associated with substantial compensatory movements, leading to high load on joints, orthopedic complications, and high fall-risk. In contrast to traditional passive assistive devices such as orthoses, powered assistive devices, frequently termed dermo- or exoskeletons, have a very high potential for compensating muscle weakness and regain mobility and independence. Devices such as the ReWalk or the Indego use rigid structures, in parallel to the user's legs, and electric motors to stabilize the human against gravity during standing and walking. Thus far, these systems have been used mostly in clinical environments for gait rehabilitation in neurological conditions (e.g. spinal cord injury, post-stroke syndrome). Their weight, which can range from 13 to 48 kg , can make them difficult to use and transport, thus limiting their applicability beyond clinical environments. However, for assistive devices to be used in everyday life, they must provide assistance across activities of daily living (ADLs) in an unobtrusive manner. Wearable motion assistance systems, especially those dedicated to lower limbs are highly promising for ambulant patients with neuromuscular disorders (e.g. FSHD, LGMD, SIBM or PD). In these conditions, the prevalence of lower-limb muscle weakness, in particular in proximal muscle groups (i.e. providing strength/torque to hips and knees) is very high. Schmidt et al. recently introduced a powered knee-hip soft exoskeleton (the Myosuit), a soft, wearable device designed to provide continuous assistance at the hip and knee joint when working with and against gravity in ADLs. This robotic device combines active and passive elements with a closed-loop force controller designed to behave like an external muscle (exomuscle) and deliver gravity compensation to the user. With 5.6 kg including batteries, the Myosuit is one of the lightest untethered devices capable of delivering gravity support to the user's knee and hip joints. In healthy subject, the Myosuit has been shown to effectively assist its users in gravity-intensive ADLs, such as sitting transfers. However, the effect of the device on movement parameters and user perception must be clarified. We believe that ambulant patients with neuromuscular disorders can highly benefit from a system that provides mobility assistance like the Myosuit. The use of such a device has the potential to shift the loss of ambulation/transfer abilities to a higher age and might mitigate disease progression and occurrence of complications. Whether the Myosuit may be safe, usable, and efficient in ambulant patients with neuromuscular disorders, remain to be specifically investigated.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - 18 years and < 70 years of age - Height between 1.50 m and 1.95 m - Weight between 45 kg and 110 kg - Abdominal perimeter < 125 cm - Written informed consent - Affiliate or beneficiary of a social security scheme - Able to comply with all protocol requirements - Confirmed diagnosis of a pathology belonging to one of the following family*: - Primary disorders of muscles - Muscular dystrophy - Congenital myopathies - Idiopathic inflammatory myopathy - Mitochondrial myopathies - Metabolic disorders - Inborn errors of metabolism - Glycogen storage disease - Functional capacities: - Able to stand up from a chair with armrest without other supports at least 3 times and at most 15 times in 30 seconds. - Report the ability to walk without the assistance of a person at least 2min - The use of traditional orthoses and walking aids will be accepted excepted knee orthoses and walkers (e.g. canes/crutches, ankle foot orthosis). Exclusion Criteria: - Unable to participate in the study - Inability to comply with protocol requirements - Guardianship/trusteeship - Pregnant or nursing women - Unstable Cardiomyopathy - Symptomatic orthostatic hypotension - Medical history of osteoporotic fracture - Balance disorder with extra neuromuscular causes - Recent trauma (fall, accident, ...) - Unstable Cardiomyopathy - Severe respiratory insufficiency - Flexion contracture in the knee and hip joint in excess of 10° - Varus malposition in excess of 10° or valgus malposition in excess of 10°

Study Design


Intervention

Device:
Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland)
Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.

Locations

Country Name City State
France Institute of Myology Paris

Sponsors (1)

Lead Sponsor Collaborator
Institut de Myologie, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absence of adverse effect attributable to the use of the device during task performed within a knee-hip powered soft exoskeleton Through study completion, on average 4 weeks
Secondary Variation in the 2 Minutes Walking Test distance (express in meters) when performed using versus not using the device Visit 2 and 3, on average 2 weeks
Secondary Variation in the 10 Meters Walking Test performance (express in seconds) when performed using versus not using the device Visit 2 and 3, on average 2 weeks
Secondary Difference of performance with and without the device during 30 Sit To Stand Visit 2 and 3, on average 2 weeks
Secondary Difference of performance with and without the device during simple Sit To Stand Visit 2 and 3, on average 2 weeks
Secondary Difference of performance with and without the device during the squating test Visit 2 and 3, on average 2 weeks
Secondary Difference of performance with and without the device during Time Up & Go test Visit 2 and 3, on average 2 weeks
Secondary Difference of performance with and without the device during stairs climbing test Visit 2 and 3, on average 2 weeks
Secondary Variation in spatiotemporal gait parameters during the 2 Minutes Walking Test with and without the device using 3D accelerometers' system Spatiotemporal gait parameters: Cadence, Gait Speed, Step Duration, Stride Length, Cadence Asymmetry, Gait Speed Asymmetry, Stance Asymmetry, Stride Length Asymmetry Visit 2 and 3, on average 2 weeks
Secondary Variation in spatiotemporal gait parameters during the 10 Meters Walking Test with and without the device using 3D accelerometers' system Spatiotemporal gait parameters: Cadence, Gait Speed, Step Duration, Stride Length, Cadence Asymmetry, Gait Speed Asymmetry, Stance Asymmetry, Stride Length Asymmetry Visit 2 and 3, on average 2 weeks
Secondary Variation in kinematics parameters during 30 Sit To Stand with and without the device using 3D accelerometers' system Kinematics parameters: Gait Joint Angles, Stick Plot Visualization - Sagital plane, Hip-Knee & Knee-Ankle Plots Visit 2 and 3, on average 2 weeks
Secondary Variation in kinematics parameters during unique Sit To Stand with and without the device using 3D accelerometers' system Kinematics parameters: Gait Joint Angles, Stick Plot Visualization - Sagital plane, Hip-Knee & Knee-Ankle Plots Visit 2 and 3, on average 2 weeks
Secondary Variation in kinematics parameters during Time Up & Go evaluation with and without the device using 3D accelerometers' system Kinematics parameters: Gait Joint Angles, Stick Plot Visualization - Sagital plane, Hip-Knee & Knee-Ankle Plots Visit 2 and 3, on average 2 weeks
Secondary Variation in kinematics parameters during stairs climbing test with and without the device using 3D accelerometers' system Kinematics parameters: Gait Joint Angles, Stick Plot Visualization - Sagital plane, Hip-Knee & Knee-Ankle Plots Visit 2 and 3, on average 2 weeks
Secondary Modification of lower limb muscle recruitment measured by surface EMG with and without the device Visit 2 and 3, on average 2 weeks
Secondary Variation in postural stability measured by force platform with and without the device Mean Velocity, RMS Sway Visit 2 and 3, on average 2 weeks
Secondary Modification in scoring of the device measured by the Modified Nordic Questionnaire Through study completion, on average 4 weeks
Secondary Positive scoring of device efficiency measured by the System usability scale Through study completion, on average 4 weeks
See also
  Status Clinical Trial Phase
Terminated NCT01480245 - Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy Phase 3
Completed NCT01153932 - Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy Phase 2
Completed NCT00027391 - Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD) N/A
Recruiting NCT04392518 - Telerehabilitation in Proximal Muscle Weakness N/A
Completed NCT03851107 - The Effectiveness of Participation-focused Interventions on Body Functions of Youth With Physical Disabilities N/A
Completed NCT01462292 - A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) Phase 2
Recruiting NCT06094205 - Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02) N/A
Recruiting NCT05724173 - Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia N/A
Recruiting NCT03698149 - ECoG BMI for Motor and Speech Control N/A
Active, not recruiting NCT03811301 - [BrainConnexion] - Neurodevice Phase I Trial N/A
Completed NCT05881122 - Anti-inflammatory Diet Consultation for Those With Neuromuscular Disability N/A
Completed NCT04154098 - Evaluation of a Textile Scapula Orthosis N/A
Recruiting NCT05409079 - Schulze Muscular Dystrophy Ability Clinical Study N/A
Enrolling by invitation NCT04009408 - Expiratory Muscle Strength Training (EMST) in Neuromuscular Disorders N/A
Active, not recruiting NCT00674843 - The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies Phase 1
Recruiting NCT02109692 - Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies N/A
Active, not recruiting NCT04045158 - Diaphragm Ultrasound in Neuromuscular Disorders
Not yet recruiting NCT03508583 - Turkish Version of The Measure of Processes of Care (MPOC)
Terminated NCT01803412 - A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects Phase 3
Completed NCT03406780 - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Phase 2